|
|
|
|
|
02.09.25 - 14:33
|
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that Rick Stewart, CEO of Achieve Life Sciences, will be participating at two upcoming conferences. Details are as follows:...
|
|
|
21.08.25 - 20:54
|
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years (Benzinga)
|
|
|
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market.
Latest Ratings for ACHV
DateFirmActionFromTo Oct 2021Alliance Global PartnersInitiates Coverage OnBuy Jun 2021OppenheimerInitiates Coverage OnOutperform Sep 2020Lake StreetInitiates Coverage OnBuy
View More Analyst Ratings for ACHV
View the Latest Analyst Ratings
read more...
|
|
|
|
|
29.07.25 - 14:33
|
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025....
|
|
|
08.07.25 - 12:30
|
Achieve Life Sciences: Trading-Chance bei Anti-Raucher-Aktie (Sharedeals)
|
|
|
SD-Leser kennen die Aktie von Achieve Life Sciences von früheren Höhenflügen noch gut. Immer wieder konnten wir uns gezielt Trading-Dynamiken zunutze machen und teils dreistellige Gewinne einfahren. Auch diesmal? Achieve Life Sciences ist ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das derzeit keine Produkte am Markt hat. Es konzentriert sich auf die Entwicklung von Cytisinicline, […]
The post Achieve Life Sciences: Trading-Chance bei Anti-Raucher-Aktie first appeared on sharedeals.de....
|
|
|
01.07.25 - 01:54
|
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters′ Option to Purchase Additional Securities (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to purchase additional shares of common stock and/or accompanying warrants. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $45.0 million....
|
|
|
|
|
|
|
27.06.25 - 05:45
|
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants to purchase up to an additional 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) in connection with the public offering....
|
|
|
|
|
26.06.25 - 22:06
|
Achieve Life Sciences Announces Proposed Underwritten Public Offering (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof) offered in the public offering. All of the securities are being offered by Achieve. The offering is subject to market and other conditions, and...
|
|
|
|
|
|
|
28.05.25 - 14:33
|
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5, 2025, in New York City....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
